The Effectiveness of HESA-A Supplement Combined with Atorvastatin on Nonalcoholic Fatty Liver in Rats

Fatty liver disease occurs due to disturbances in lipid metabolism (increased fat synthesis and halting of catabolism) which eventually leads to the accumulation of large amounts of fat (triglycerides) in liver cells, that if left untreated lead to inflammation and cirrhosis. This study aimed to investigate the effect of concomitant use of HESA-A and atorvastatin on biochemical parameters in non-alcoholic fatty liver disease compared with atorvastatin alone.
Methods and Materials: 28 rats weighing 180±20 g were randomly divided into two groups: a control group (n = 7) with standard diet and a HFD (high-fat diet) group (n=21) which were fed for 8 weeks. To confirm the induction of fatty liver; controls along with seven rats from the HFD group were killed. The remaining 14 animals were divided into two groups. The first group received atorvastatin and the second group received HESA-A in combination with atorvastatin daily for 30 days. Finally, biochemical parameters (glucose, lipid profile and liver enzymes) were measured and histological studies were performed on the liver samples.
Biochemical parameters in the HESA-A combined with atorvastatin group were significantly decreased in comparison to the atorvastatin group (p According to the results of this study, the use of HESA-A as a complementary treatment for fatty liver disease without side effects can be integral role in reducing the incidence of non-alcoholic fatty liver disease, especially in severe cases.